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Abstract
Neurofibromatosis type 1 (NF1) is a dominantly inherited multi-system disorder. Major features
include pigmentary abnormalities, benign tumors of the nerve sheath (neurofibromas), malignant
tumors, learning disabilities, and skeletal dysplasia. The NF1 gene functions as a tumor suppressor,
but haploinsuffiency probably accounts for some aspects of the non-tumor phenotype. The protein
product, neurofibromin, is a Ras GTPase-activating protein, and various Ras pathway inhibitors are
being tested in preclinical models and clinical trials for effectiveness in treating NF1 complications.
This month in BMC Medicine, a paper by Kolanczyk et al describes a preclinical mouse model for
tibial dysplasia and provides evidence that the drug lovastatin – in use to treat cardiovascular
disease – may be beneficial, opening the door to clinical trials in humans.
Patients with neurofibromatosis type 1 (NF1) are largely
sustained by the hope that advances in research will result
in new forms of treatment. The NF1 gene was identified in
1990 and was quickly found to encode a GTPase activat-
ing protein (GAP) whose target is the oncoprotein Ras.
However, despite great progress in the dissection of cell
signaling pathways involved in the disorder, there is still
no definitive treatment to prevent or reverse the complica-
tions. The path from bench to bedside may be the best
approach, but the challenges should not be underesti-
mated. There are, however, recent signs that provide hope
that this approach will pay off. The paper by Kolanczyk et
al published this month in BMC Medicine describes a pre-
clinical mouse model for one of the most difficult NF1
lesions to treat, tibial dysplasia, and provides evidence
that an existing drug with a known safety profile in chil-
dren, lovastatin, may be beneficial, opening the door to
clinical trials in humans.
NF1 poses a particular challenge given the complex and
highly variable phenotype [1]. The condition is one mem-
ber of a group of disorders collectively referred to as 'neu-
rofibromatoses', which includes NF1, NF2, and
schwannomatosis. Each is associated with a distinct spec-
trum of nerve sheath tumors, and each is dominantly
transmitted, due to mutation in a different gene. The hall-
mark lesion of NF1 is the neurofibroma, a benign tumor
consisting of Schwann cells, fibroblasts, perineurial cells,
and mast cells. Patients with NF1 may develop innumera-
ble tumors on the skin, internal tumors, and large disfig-
uring tumors along major peripheral nerves. Other
features include pigmentary lesions (café-au-lait macules,
skin-fold freckles), learning disabilities, malignant tumors
(gliomas and malignant peripheral nerve sheath tumors),
and skeletal dysplasias.
NF1 patients may suffer from both focal and generalized
skeletal disorders. Among focal disorders, long bone dys-
plasia, most commonly involving the tibia, can be a major
source of morbidity [2]. Tibial dysplasia presents in
infancy with bowing of the lower leg. The dysplastic bone
is prone to fracture, and these fractures are very difficult to
treat. Pseudoarthrosis ('false joint') may occur, and some
patients still require amputation. Non-ossifying fibromas
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may also occur, sometimes leading to pain or even to frac-
ture. The generalized dysplasia consists of decreased bone
mineral density [3-6], as well as slow healing following
injury or orthopedic surgery.
Tumors occur in NF1 patients by a classic two-hit model,
indicating that the NF1 gene is a tumor suppressor [7,8].
A subset of Schwann cells within neurofibromas have
mutations of both NF1 alleles, the first being the germline
mutation and the second being acquired. Large plexiform
neurofibromas probably acquire their second hits during
development, whereas smaller dermal tumors may
acquire theirs later in life. Malignant tumors likely occur
upon accumulation of additional genetic changes. At least
some non-tumor manifestations also involve a two-hit
mechanism: NF1 homozygously mutated cells have been
found in melanocytes from café-au-lait macules [9] and in
cells isolated from dysplastic tibial lesions [10].
Haploinsufficiency of NF1 may also play a pathogenetic
role for some features. This appears to be the case for the
cognitive phenotype, some aspects of which are modeled
in mice rendered heterozygous for Nf1 mutation (Nf1 +/-
) [11,12]. It might also explain the diffuse skeletal pheno-
type of osteopenia. The NF1 gene is expressed in chondro-
cytes, as well as osteoblasts, osteoclasts, and periosteal
cells, and the Ras signaling pathway is hyperactive in these
cells and in bone marrow-derived osteoprogenitors in Nf1
+/- mice [13,14]. The progenitor cells show increased pro-
liferation and decreased ability to differentiate into oste-
oblasts [15]. The Nf1 heterozygous mice do not develop
tibial dysplasia, but Kolanczyk et al [16] did obtain mice
with tibial bowing by homozygous inactivation of Nf1 in
developing limbs using a conditional knock-out system.
Osteoblasts were found to display increased proliferation
but impaired ability to mineralize [16].
Given the role of neurofibromin in stimulating the con-
version of Ras-GTP to Ras-GDP, proteins involved in the
Ras signal transduction pathway have been identified as
potential therapeutic targets. Clinical trials are underway
with several existing compounds [17], and several preclin-
ical models have been used in drug testing. Both existing
compounds with known action on this pathway, and
newly identified compounds are of interest.
The Nf1 +/- mouse model has been used, as already noted,
to model learning disabilities. The phenotype is rescued
by genetic crosses that reduce Ras-GTP in the brain, as well
as by treatment with a farnesyl transferase inhibitor,
which blocks Ras binding to the cell membrane [18].
Recently, Li et al [19] demonstrated that lovastatin also
rescues the cognitive defect, presumably by virtue of its
effect on membrane binding of Ras. This has opened the
door to clinical trials in children with NF1, since the safety
profile of statins in children is known. One negative statin
trial has recently been reported [20], and another using a
different drug for a longer period of treatment is being
planned.
The paper by Kolanczyk et al in this volume of BMC Med-
icine  [21] represents the second report of a favorable
response to lovastatin in a mouse model, and the first of
preclinical treatment aimed at skeletal dysplasia. The con-
ditional knock-out animals display tibial bowing, but do
not spontaneously develop fractures, presumably because
of different mechanical loads on mouse bones as com-
pared with human. Kolanczyk et al have modeled the tib-
ial fracture by drilling a small hole in the tibia and then
monitoring the healing process. Wild-type animals com-
pletely heal within 28 days, whereas the knock-out mice
display slower and less complete healing. Treatment of
the animals with lovastatin resulted in markedly
improved bone healing, and normalization of MAPK sig-
naling as compared with untreated animals.
Skeletal dysplasia may thus be another target of lovastatin
therapy in clinical trials for patients with NF1. Improve-
ment of bone healing in children with tibial dysplasia
would be welcomed, given the enormous difficulty in the
management of this complication and the severe associ-
ated morbidity. Whether statin treatment will have other
benefits related to bone mineral density remains to be
determined. Moreover, there is a possibility that these
findings will have an impact on the management of bone
disorders in non-neurofibromatosis-affected individuals
as well. When patient-advocates argue to increase funding
for research on neurofibromatosis, one of the potential
benefits cited is that this work will shed light on common
disorders such as cancer, learning disabilities, and oste-
oporosis. The NF1 gene clearly plays a role in normal
bone development and metabolism, and there is indeed a
possibility that pathogenetic and therapeutic insights
gained from this rare disorder may someday benefit a
much larger population.
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